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ABSTRACT 
Campylobacter jejuni clone SA has recently emerged as the prevalent cause of 
Campylobacter-associated sheep abortion in the United States. To develop effective 
vaccines against C. jejuni clone SA in sheep, it is necessary to identify the antigens 
that elicit protective immune responses. Recently, by using immunoproteomic 
approaches we successfully identified a number of clone SA proteins that were 
consistently immunoreactive with multiple convalescent sheep and guinea pig sera. In 
this study, as a first step towards developing an efficacious subunit vaccine against 
sheep abortion, we began to further characterize these proteins. Accordingly, 7 clone 
SA proteins were selected, which included HtrA, CgpA, CJSA_0852, Peb4, FabG, 
MetK and FlgL. Recombinant proteins for each of these antigens were produced in an 
E. coli expression system, and their reactivity with a panel of convalescent sera 
obtained from C. jejuni-infected ewes and guinea pigs were tested using 
immunoblotting. The results showed that CgpA, MetK, FabG had the strongest 
antigenicity, while HtrA, FlgL and Peb4 were less antigenic, and CJSA_0852 had little 
reactivity with the sera tested. CgpA, HtrA and FlgL were chosen to further evaluate 
the induction of protective immunity against bacterial challenge in the mouse model of 
systemic infection and bacteremia. Immunization of mice with recombinant CgpA, 
HtrA and FlgL induced high level of specific antibodies, but only CgpA-immunized 
mice showed a significant decrease in the level of bacteremia compared with the 
control mice. Analysis of different cellular fractions demonstrated that CgpA is a 
periplasmic protein. These results indicate that CgpA may be a potential subunit 
vaccine candidate against sheep abortion caused by C. jejuni. 
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CHAPTER 1.  GENERAL INTRODUCTION 
Introduction  
C. jejuni has become one of the most predominant etiologic agents of acute 
gastroenteritis in humans all over the world (1), which leads most research of 
Campylobacter to focus on C. jejuni. Patients who are susceptible to 
Campylobacter infection are different between developing and developed 
countries. Campylobacter infection is also one of the most predominant causes of 
ovine abortion worldwide (2). Infection is mostly associated with oral exposure to 
infected products of parturition (3). Historically, C. fetus subsp. fetus was regarded 
as the majority of the Campylobacter spp. associated with ovine abortion, 
nevertheless, recent studies pointed that C. jejuni is increasingly related with ovine 
abortions, instead of C. fetus (2-7). Although the highly variable genetics and 
strains of Campylobacter associated with sheep abortion worldwide, in the United 
States there is a predominant C. jejuni clone causing the majority of 
Campylobacter-associated ovine abortions (named clone SA for sheep abortion) 
(2). This is a surprising finding and demonstrates that clone SA has developed 
means to adapt to the agricultural practices in sheep production and/or owns novel 
virulence traits, which have facilitated its dominance as a successful pathogen in 
the United States. Furthermore, C. jejuni clone SA poses an important threat to 
public health due to zoonotic transmission of this emergent clone to humans mainly 
via raw milk, which has been recently demonstrated by molecular and 
epidemiological evidence (8). Moreover, it is possible that chemoprophylaxis 
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might have in part enhanced the emergence of this tetracycline-resistant clone 
because tetracyclines are commonly used in the United States for the prevention 
and treatment of campylobacteriosis in sheep (2, 9).  
C. jejuni is an enteric pathogen and is transmitted mainly via the fecal-oral 
route. To cause an infection, first, C. jejuni must be able to tolerate the acidity in 
the stomach and colonize the intestines (10-12). Colonization of the gut mucosa is 
determined by the corkscrew morphology, flagellar motility, and its ability of 
adhesion to the mucosal layer (11, 12). Once colonized, the organism may trigger 
inflammation and epithelial cell damage with fluid secretion (13). As with other 
bacterial pathogens, almost all Campylobacter virulence factors are located on the 
bacterial cell surface or are secreted (14). 
It is widely believed that a vaccine must be able to stimulate intestinal 
immunity to be effective against an enteric bacterial pathogen (15-18). Three 
different strategies have been considered for the development of a reliable vaccine 
against C. jejuni. The first strategy is live attenuated Campylobacter vaccine, 
which is considered as an attractive approach (19). Nevertheless, a study using a 
viable non-colonizing strain of C. jejuni failed to elicit protective immunity in 
chicks (20). Furthermore, the association of the neuropathy and autoimmune 
disease Guillain–Barre syndrome (GBS) with C. jejuni infections impedes the 
development of whole cell vaccines (21). The second one is killed whole cell 
vaccine, which can offer several advantages as potential vaccines for mucosal 
immunization. Due to their microparticle nature, whole dead cells should enhance 
the interactions between their surface and mucosal lymphoid tissues (22). A recent 
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study has demonstrated that a limited protection was conferred by C. jejuni killed 
cells after oral vaccination in ferrets (23). Using specific proteins/antigens of 
Campylobacter as subunit protein vaccines is another promising strategy for 
vaccination. Two Campylobacter antigens, PEB1 and flagellin (24, 25), have been 
evaluated as vaccine candidates. However, Campylobacter flagellins have different 
levels of glycosylation and high antigenic diversity, which makes the development 
of a flagellin-based vaccine problematic (26, 27). A recent study also demonstrates 
that significant levels of anti-PEB serum IgG did not protect against C. jejuni after 
oral challenge in mice (28). In this study, we selected 7 of these proteins to 
evaluate their potential as subunit vaccine candidates. The selection is based on the 
predicted functions, cellular localization, consistent sero-reactivity, and sequence 
conservation among C. jejuni. This list included 3 periplasmic proteins (HtrA, 
CgpA, CJSA_0852), one outer membrane protein (Peb4), two cytoplasmic proteins 
(FabG and MetK), and one extracellular membrane protein (FlgL). Our results 
suggest that CgpA may be a promising subunit vaccine candidate against sheep 
abortion caused by C. jejuni. 
 
Thesis Organization 
This thesis consists of three chapters. The first chapter is a literature review 
that includes a general overview of Campylobacter (mainly C. jejuni) and 
Campylobacter abortion, virulence factors of Campylobacter and Current vaccine 
development. The second chapter talks about Immunogenic and protective 
properties of recombinant proteins from a highly pathogenic Campylobacter jejuni 
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clone associated with sheep abortion. The third chapter is a general conclusion. The 
references cited throughout the text are located immediately after each chapter. 
 
Literature review 
Campylobacter: microbiology and genetics 
Campylobacter, a genus of small and gram-negative microorganisms that have 
curve or spiral shaped morphology, has attracted broad attention and research 
efforts over the last decades. Most Campylobacter species are motile bacterial 
organisms with one or two unsheathed polar flagella attached to their polar ends 
(29, 30). Campylobacter jejuni is inhabitant in a microaerophilic environment for 
optimal growth at 5% O2, 10% CO2 and 85% N2 between 37 °C to 42 °C (31, 32). 
Campylobacter spp. are relatively fastidious organisms, which do not usually make 
use of carbohydrates, but utilize amino acids as the main carbon source (33). 
The first reports of the organism originated from an investigation on epizootic 
abortion of cattle initiated at the request of the British Board of Agriculture and 
Fisheries in 1913 (34, 35). In 1927, Smith and Orcutt discovered a microorganism 
isolated from feces of the cattle, which were infected with diarrhea, and named this 
bacterium as Vibrio jejuni (36). Later, another bacterium was isolated from feces of 
diarrheal pig, which was named Vibrio coli by Doyle in 1944 (33, 36, 37). The 
disease in humans was first reported from outbreak of enteritis in 1938 due to 
unpasteurized milk (38). Fecal cultures were negative, but fecal smears and blood 
cultures were observed to contain V. jejuni-like organisms (35, 38) 
 
 
 
5 
The genus Campylobacter was initially known as V. fetus and V. bubulus in 
1963 (39). Separation from Vibrio was later proposed due to the low G+C content, 
non-fermentative metabolism and microaerophilic growth nature of Campylobacter 
(40). Currently, the genus Campylobacter consists of more than 25 heterogeneous 
species, which are C. coli, C. jejuni, C. lari, C. fetus, C. upsaliensis, C. helveticus, 
C. hyointestinalis, C. concisus, C. mucosalis, C. curvus, C. rectus, C. showae, C. 
gracilis and C. sputorum and other more. It is possible, but not always reliable to 
differentiate between Campylobacter species by traditional biochemical methods 
and growth characteristics, especially for the biochemical tests (39). For instance, 
based on the growth temperature, Campylobacter species have been characterized 
as non-thermophilic, such a C. fetus, and thermophilic such as C. jejuni and C. coli 
(41, 42). Molecular methods are commonly used to differentiate Campylobacter 
species and subspecies today. Some examples include restriction length fragment 
polymorphism (RFLP), pulse field gel electrophoresis (PFGE), multi-locus 
sequence typing (MLST), and amplification/sequencing of 16S/23S rRNA genes or 
species specific genes by PCR (8, 43-46). 
C. jejuni is the main pathogenic specie implicated in human infections, which 
leads most research of Campylobacter to focus on C. jejuni. Currently an 
increasing number of C. jejuni strains are being whole-genome sequenced, which 
include RM1221, 81-176, 81116, IA3902, ICDCCJ07001, M1, S3, NCTC 11168, 
260.94, CG8421, CG8486, BH-01-0142, HB93-13, CF93-6, 84-25 and doylei. A 
rather small circular chromosome, which is only 1.6 to 1.8 megabases, exists in C. 
jejuni with low G+C content (47), which is especially low in the 
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lipooligosaccharide (LOS) and extracellular polysaccharide (EP) regions (48). C. 
jejuni can take up DNA directly from the environment and produce more genetic 
diversity, including the development of antibiotic resistance (12). The genome of 
C. jejuni contains a high rate of variable sequences particularly in the genes of 
modification or biosynthesis in surface structures (49). Multiple genome sequences 
of C. jejuni strains with different phenotypic traits have demonstrated the 
epidemiology and pathobiology of this organism through the use of comparative 
genomics.   
 
Human campylobacteriosis  
C. jejuni has become one of the most predominant etiologic agents of acute 
gastroenteritis in humans all over the world (1). Patients who are susceptible to 
Campylobacter infection are different between developing and developed 
countries. Campylobacteriosis occurs in all ages, especially for children who are 
less than 4 years old and adults who are 15 to 39 years old in developed countries 
(50). In contrast, developing countries witness a peak in clinical cases during 
childhood and then a sharp decline in cases with age (29). Additionally, in 
developed countries, C. jejuni infection is more serious than in developing 
countries. The prevalence of asymptomatic infections are approximately 15% in 
developing countries (29). This appears to be mimicked in developed countries 
where occupationally exposed individuals, such as poultry abattoir workers, 
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experience clinical disease in the initial stage of employment, but rarely develop 
clinical disease as employment continues (29, 50, 51).  
Campylobacteriosis typically has an incubation period of 1-2 days (52). 
Symptoms include fever, nausea, bloody and watery diarrhea, and abdominal pain 
with fever sometimes starting 1-2 days before diarrhea (52). It takes approximately 
2-5 days to develop to acute diarrhea after infected with Campylobacter. Generally, 
the symptoms can persist nearly two weeks. Only about 15% of infected persons 
vomit, though most patients feel nauseous (11). Immunocompromised individuals, 
particularly those with humoral immune deficiencies like AIDS tend to have more 
severe disease with bacteremia (29). One third of patients may have influenza 
virus-like clinical symptoms like headache, fever, myalgia and dizziness before 
they suffer from diarrhea. This phenomenon indicates that systemic immune 
response influences the effect of local infection (29, 53). Furthermore, the variable 
phenotypic expressions of the disease also associate with diversity of bacterial 
virulence ability and immune response from different hosts (54, 55). 
 Post-infectious sequelae, like Guillian Barre syndrome (GBS) and reactive 
arthritis (ReA), may appear after acute phase for some individuals with self-
limiting of Campylobacter infections (29, 56, 57). GBS is a disease defined as “a 
progressive motor weakness of more than one limb with low or absent reflexes” by 
Asbury and Cornblath (57, 58). Reactive arthritis is a sterile inflammation of the 
joints occurring within 4 weeks of a bacterial intestinal or urinary infection (56). 
Both GBS and ReA are believed to result from autoimmune disease secondary to 
immune recognition of C. jejuni like molecules, noted as molecular mimicry (56, 
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57). Previous studies indicate that the primary reason of GBS caused by 
Campylobacter is molecular mimicry, which happens between structures on the 
LOS (lipooligosaccharides) of some Campylobacter strains and peripheral nerve 
glycolipids or myelin proteins (1, 59). 
 
Ovine campylobacteriosis 
One of the most vital factors related with the profitability of small ruminant 
operations is reproductive performance (60). Moreover, such epizootics of abortion 
of small ruminants might cause severe economic losses (61). Campylobacter 
infection is one of the most predominant causes of ovine abortion worldwide (2). 
Infection is mostly associated with oral exposure to infected products of parturition 
(3). However, it is quite common that water supplies are also contaminated by 
Campylobacter of feces origin (62) and the time of fecal excreting of the organism 
has been observed to increase with the rate of abortion in sheep flocks (3). 
Historically, C. fetus subsp. fetus was regarded as the majority of the 
Campylobacter spp. associated with ovine abortion, nevertheless, recent studies 
pointed that C. jejuni is increasingly related with ovine abortions, instead of C. 
fetus (2-7). Kirkbride et al. first reported this shift in the late of 1980s (6), and the 
proportion of C. jejuni isolates in ovine abortion has increased substantially in 
recent years (2, 5). Although genetically diverse strains of Campylobacter are 
associated with sheep abortion worldwide, in the United States there is a 
predominant C. jejuni clone causing the majority of Campylobacter-associated 
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ovine abortions (named clone SA for sheep abortion) (2). This is a surprising 
finding and demonstrates that clone SA has developed means to adapt to the 
agricultural practices in sheep production and/or owns novel virulence traits, which 
have facilitated its dominance as a successful pathogen in the United States. 
Furthermore, C. jejuni clone SA poses an important threat to public health due to 
zoonotic transmission of this emergent clone to humans mainly via raw milk, 
which has been recently demonstrated by molecular and epidemiological evidence 
(8). Moreover, it is possible that chemoprophylaxis might have in part enhanced 
the emergence of this tetracycline-resistant clone because tetracyclines are 
commonly used in the United States for the prevention and treatment of 
campylobacteriosis in sheep (2, 9). 
The pathogenesis of ovine campylobacteriosis is shown to entail ingestion of 
contaminated material after oral exposure (63) with mucosal invasion and placental 
localization subsequent to intestinal colonization (64). Campylobacter can be 
carried in the gall bladder and intestines of healthy sheep with no risks of clinical 
diseases (2, 65-67). Previous studies have reported that gall bladder colonization by 
C. fetus follows oral inoculation (68), intravenous inoculation (69, 70), natural 
abortion (68), and in ewes intravenously inoculated, gall bladder colonization was 
always related with concurrent intestinal colonization (70), thus supporting the 
potential role of gall bladder colonization in overall disease epidemiology  and in 
the development of carrier ewes (69). Infection in sheep is predominantly intestinal 
(71), and involvement of the uterus is regarded by some to be an accidental result 
of bacteremia in non-immune pregnant ewes. However, systemic infections can be 
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caused by highly virulent C. jejuni strains which can invade into circulation (72). 
One significant step in the pathogenesis of Campylobacter-associated abortion is 
accessing to the blood stream and systemic spread followed by invasion of the 
intestinal epithelium. For C. fetus subsp. fetus, systemic infection is depended on 
the expression of surface layer (S-layer) proteins (73), which suppress complement 
3b (C3b) binding (74) and therefore inhibit complement mediated killing 
mechanisms. Nevertheless, these proteins are not expressed by C. jejuni. 
Pathogenic isolates of C. jejuni are thought to have a microtubule dependent 
invasion system (75), and generally invasive (76), whereby bacteria travel along 
microtubules to the perinuclear area (77) after taken into an endosomal vacuole and 
then replicate within intestinal cells (77). These internalized bacteria move within 
vacuoles (78) to the basolateral membrane for exocytosis (75). The presence of 
functional flagella is a critical factor in cellular uptake of C. jejuni (79) and 
efficient colonization (80, 81), whereas flagellar paralysis allows adherence instead 
of  invasion of eukaryotic cells (82). Many strains of C. jejuni, as well as C. fetus 
and C. coli, generate cytolethal-distending toxin (CDT) (83), a nuclease that 
induces double strand breaks in DNA of both non-proliferating and proliferating 
host cells, thereby resulting in cell death or cell cycle arrest (84). These dying or 
dead cells in the mucosa may cause considerable disruption of the epithelial barrier 
to allow bacteria invade into the lamina propria. In sum, these findings provide an 
overall understanding of the pathogenesis of septic abortion associated with 
Campylobacter spp.; nevertheless, the mechanisms of the observed variation in 
 
 
 
11 
virulence between Campylobacter strains and species and the requisite steps in this 
process remain further explored. 
 For pregnant ewes that are susceptible to infection, initial exposure may cause 
intestinal invasion, followed with placentitis, fetal infection and abortion, which 
commonly occurs in the last third period of pregnancy (3, 72, 85, 86). During the 
initial stage of infection, there is no signs of clinical disease in the ewes; however, 
ewes may die due to uterine sepsis and septicemia occasionally if the fetus dies and 
remains in utero (2, 3). Abortion generally takes place 7 to 25 days post-exposure 
(61) and initially, only a small quantity of ewes abort, followed by a rapid increase 
in abortion (i.e., abortion storms) 2 to 3 weeks later (87). If the start of placental 
infection is delayed until the very late stages of pregnancy, lambs may be born live, 
but are typically too weak to survive. 
 Thickened uterine walls with edema, swollen caruncles and placentas with 
mottled swollen cotyledons are typical lesions in aborted ewes (88). Aborted 
fetuses can be autolyzed mildly to severely and have serosanguinous fluid in the 
thorax and abdomen, and focal liver necrosis (2, 3, 88, 89). Generally, lesions are 
focused on the placentomes whereas the intercotyledonary spaces are less severely 
infected (71). Fetal lesions are not always the same and the characteristics include 
nonspecific edema, suppurative bronchopneumonia and random necrotizing 
hepatitis with a targetoid gross appearance (71). Histologically, the aborted 
placentas have the signs of acute suppurative placentitis with necrosis of 
cotyledons and congestion; trophoblasts can be distended with intracytoplasmic 
organisms that can be stained with Giemsa stain (88, 89). 
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Virulence factors of C. jejuni 
C. jejuni is an enteric pathogen and is transmitted mainly via the fecal-oral 
route. To cause an infection, first, C. jejuni must be able to tolerate the acidity in 
the stomach and colonize the intestines (10-12). Colonization of the gut mucosa is 
determined by the corkscrew morphology, flagellar motility, and its ability of 
adhesion to the mucosal layer (11, 12). Once colonized, the organism may trigger 
inflammation and epithelial cell damage with fluid secretion (13). As with other 
bacterial pathogens, almost all Campylobacter virulence factors are located on the 
bacterial cell surface or are secreted (14). Below is the description on some of the 
best characterized virulence factors involved in Campylobacter pathogenesis.  
 
      a) Flagella  
In the period of hosts’ infection, C. jejuni lives primarily within the thick 
mucus layer lining the intestinal epithelium (90-92). C. jejuni flagella and its 
corresponding motility are of utmost importance in the pathogenic process, 
including host cell invasion and protein secretion, and host colonization; non-
motile C. jejuni strains are attenuated for colonization of human or animal hosts 
(93-95). Moreover, Wassenaar and Blaser (52) concluded that  aflagellated C. 
jejuni mutants displayed a dramatic decline of internalization by host cells, 
indicating the significant role flagella plays in invasion. Two different viscosity 
dependent modes of motility exists in C. jejuni in cecal mucosal scrapings from 
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infected mice (92). At low viscosity, C. jejuni swims via rather straight vertical 
movements without direction changes (96, 97). While at high viscosity, a darting 
motility characterized by oscillation along a relatively short and straight path is 
observed (97, 98). Regarding the structure, the flagellar filament is comprised of 
flagellin subunits encoded by FlaA (major) and FlaB (minor) (99). Whereas FlaA is 
essential for flagellation and motility, the requirement of FlaB varies among 
Campylobacter species (100-103). A two-component system, including the sensor 
FlgS and the response regulator FlgR, is crucial in the control of the transcriptional 
expression of Campylobacter flagellum (104). The flagellar hook is primarily 
composed of the protein FlgE and hook-filament junction proteins FlgK and FlgL. 
The C. jejuni FlgL mutant is not capable of exporting and delivering the 
Campylobacter invasion antigens, Cia proteins (105). Apart from agglutination, 
attachment and biofilm formation, bacterial flagella also enable chemotaxis that 
plays a vital role in both the commensal and pathogenic lifestyle of C. jejuni (12). 
Initially, C. jejuni was reported to be attracted to amino acids, carbohydrates and 
organic acids (106). Several of these responses, however, were subsequently found 
to occur in non-chemotactic mutants and thus represent false-positive responses 
(107). Several compounds have withstood additional chemotaxis assays, however, 
fucose, pyruvate, aspartate, fumarate, and formate can be attracted for C. jejuni 
(106, 108-111). To sum up, these findings demonstrate that flagella and associated 
components are indispensable factors for the initial interaction of C. jejuni with the 
host, causing colonization of the intestine and subsequent pathology to host. 
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      b) Cell wall structures 
Several virulence factors are located in/on the cell wall of C. jejuni. There are 
three layers in the outer-membrane of Gram-negative bacteria, an outer lipoprotein 
layer, a middle lipopolysaccharide layer and an inner mucopeptide layer. The main 
component of bacterial surface is polysaccharides, which are crucial in the 
interactions among pathogens, hosts and the environment (112, 113). During the 
1990s, Aspinall and co-workers discovered that Campylobacter (C. jejuni, C. coli, 
and C. lari) exposed polysaccharides (PSs) that were considered to be O-chain PS 
regions of cell wall lipopolysaccharides (LPS) (114-119). However, subsequent 
genomic analysis demonstrated that the observed PSs of C. jejuni were actually 
capsular polysaccharide (CPS) (120). Campylobacter species, like other Gram 
negative mucosal pathogens, express a CPS, but unlike other enteric pathogens it 
possesses a lipooligosaccharide (LOS) instead of a full length LPS (121). 
Polysaccharides of C. jejuni mainly include CPS, LOS, N-linked protein glycans 
and O-linked flagellar sugars. The LOS and CPS generated from distinct strains of 
C. jejuni are diverse in structure and highly variable. A large quantities of genes in 
these hypervariable regions are also subject to phase variation, leading to 
phenotypic and genetic diversity among C. jejuni strains, which may play a crucial 
role in immune evasion during C. jejuni infection (122). 
The LOS structure is composed of a lipid A anchor and an oligosaccharide 
which has an unchanged inner core and a variable outer core, therefore it is denoted 
as LOS, for it does not contain the O-antigen, which exists in lipopolysaccharides 
(123-125). To date, the relationship between C. jejuni and the debilitating 
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neuropathy GBS has been thoroughly characterized (126, 127), in which the LOS 
structures on some C. jejuni strains resemble the human gangliosides on peripheral 
nerves. The capsular polysaccharide (CPS), which is the outermost structure on the 
bacterial cell, may play a vital role in the interaction among the pathogen, host and 
environments (127). The CPS is a key virulence factor due to its importance in 
epithelial cell adherence, serum resistance and invasion for C. jejuni (124, 128). 
CPS-based vaccine strategies have been very successful in reducing the overall 
disease incidence of several encapsulated bacteria including Neisseria meningitidis, 
Streptococcus pneumoniae, and Haemophilus influenza (129, 130) and  are 
currently in the testing phase for controlling C. jejuni infection.  Previous studies 
have shown that N-linked glycosylated proteins might play a key role in adherence, 
invasion and colonization in C. jejuni (93, 131-136). The first sequenced C. jejuni  
(strain NCTC11168) genome in 2000 confirmed that a genetic locus termed pgl 
encodes the oligosaccharyltransferase (OST) PglB, which is involved in general 
protein glycosylation (137, 138). Functional recombinant expression of the general 
glycosylation locus in Escherichia coli (139), together with the relaxed specificity 
of PglB, enable the production of novel glycoprotein combinations with potential 
applications in vaccine development (140). The most successful human vaccines so 
far are usually glycoconjugate-derived where the combination of a protein coupled 
to a glycan elicits both T-cell-dependent and T-cell-independent responses, 
evoking a protective and lasting immunity as mentioned above. 
 
 
 
 
 
16 
      c) Cytolethal distending toxin 
Cytolethal distending toxin (CDT), the only Campylobacter toxin which is 
verified to date, is thought to be a key virulence factor in this pathogen (141). It is 
produced by multiple Campylobacter spp. such as C. lari, C. jejuni, C. coli, C. 
fetus, and C. upsaliensis (104, 142). Previously, CDT was considered as 
periplasmic protein of C. jejuni, implicated in adherence, invasion of and 
cytotoxicity towards host cells (143). A recent study demonstrated that outer 
membrane vesicles (OMVs) function as the vehicle for CDT to release to the outer 
surface of C. jejuni (144). OMVs are common to a wide spectrum of Gram-
negative bacteria and are generated during the normal metabolism and cell growth 
or under stress (145, 146). Once the OMVs are free from the bacterium, they 
appear as small membrane vessels including periplasmic constituents and outer 
membrane components. OMVs may serve as delivery vehicles for bacterial 
virulence factors without typical signal sequences (147, 148) and are potentially 
rich in antigens that are the initial targets for innate and adaptive immune 
recognition (149), and thus may generate protective immunity against bacterial 
challenge when used as an immunogen (150). CDT holotoxin is comprised of three 
units which are encoded by the genes cdtA, cdtB and cdtC (151). It seems that 
CdtA and CdtC interact with CdtB to produce a tripartite CDT holotoxin, which is 
essential to deliver CdtB, the enzymatically active subunit (152). Subsequently, the 
CdtB active subunit, which shows DNaseI-like activity, breaks double strand in the 
host, causing DNA damage (153). In sum, precise role of CDT in Campylobacter 
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pathogenesis is not clear; CDT might play a critical role in the invasiveness and 
modulation of the immune response instead of inducing diarrhea directly (154). 
 
      d) Invasion and adhesion 
One of the most important aspects of virulence in Campylobacter is 
interaction with intestinal cells (155). Campylobacter adheres to intestinal cell 
lining at first and then may become internalized within the cells. The organism can 
get access to sub-mucosal tissue leading to tissue damage and inflammation, 
followed by gastroenteritis. This is thought to be the virulence mechanism of C. 
jejuni moving across epithelial cell barrier. Previous studies have confirmed certain 
putative adhesions and binding factors of C. jejuni, such as the surface exposed 
lipoprotein JlpA (156), periplasmic binding protein Peb1 (157), outer membrane 
fibronectin-binding protein CadF (158), and the auto-transporter protein CapA. The 
surface-exposed lipoprotein JlpA is essential to bind the host (156). Peb1 is the 
periplasmic protein binding component of an amino acid ABC transporter in C. 
jejuni (157), can bind glutamate and aspartate, and if they are severed as the major 
carbon source, Peb1 mutants cannot survive (159). CadF, an outer membrane 
protein (OMP), is expressed in all C. coli and C. jejuni strains. CadF is 
indispensable for maximal binding and invasion by C. jejuni by binding to the cell 
matrix protein, fibronectin (104). The CadF mutants are dramatically decreased in 
ability in chick colonization compared with the wild type (160, 161). CapA is 
another auto-transporter lipoprotein which adheres to epithelial cells in human and 
chicken (162). A number of studies with variable animal models have shown that 
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early mucosal damage can be caused by the invasion of C. jejuni in the colonic 
epithelial cells. Therefore, the invasion ability of C. jejuni has been confirmed as 
an important pathogenicity-associated factor (163-166). Nevertheless, distinct 
strains of C. jejuni show different ability to invade (167). C. jejuni strains invade 
gut intestinal cells by a microtubule- and actin filament-dependent mechanism 
(168-172). 
 
      e) Stress response  
Compared to other food-borne bacterial pathogens, C. jejuni has a limited 
ability to grow in the environment, which partially is owing to its complex 
nutritional requirements and lack of corresponding adaptive responses (104). 
Campylobacter lives on intermediates of the tricarboxylic acid (TCA) cycle as a 
source of energy and cannot readily metabolize carbohydrates due to the lack of 
glycolytic enzyme phosphofructokinase. Therefore, it seems that C. jejuni mainly 
depends on scavenging amino acids and keto acids from the host or from intestinal 
microbial ﬂora. Genome analyses concluded that C. jejuni does not possess the 
global stress response regulator RpoS, which is prerequisite for the survival of 
Gram-negative bacteria upon exposure to various types of environmental stresses 
(120).  
The ability to acquire iron in the animal host is important to pathogenic 
bacteria in establishing infection (173). Less availability of free iron in mammalian 
fluids is a main problem for C. jejuni in establishing infection. The forms for most 
of the iron in the cells are lactoferrin, transferrin, iron binding glycoproteins, heme 
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or ferritin (174). Iron sulphur proteins participate in anaerobic respiration, energy 
metabolism, electron transport and amino acid metabolism. Campylobacter is 
exposed to the reactive oxygen species in human immune response, which is 
important when it is internalized by the phagocytes. Heme compounds like hemin, 
ferric iron, ferrous iron and hemoglobin can support the growth of C. jejuni. 
Additionally, C. jejuni has many systems for siderophore-mediated uptake of iron, 
like enterochelin transport system, siderophore systems encoded by gene cj0718 
and cfr A. This iron uptake system is controlled by a global regulator, Fur, in C. 
jejuni (174).  
Most of Campylobacter species are sensitive towards high levels of oxygen 
and and are microaerophilic, including the important species (such as C. jejuni) 
directly associated with food-borne infection. Superoxide dismutase can catalyze 
the dissimilation of superoxides into hydrogen peroxide and oxygen and remove 
superoxide. Further peroxidase or catalase removes the produced hydrogen 
peroxide. Campylobacter converts hydrogen peroxide to water and oxygen under 
the help of heme cofactor and catalase (175). C. jejuni and C. coli express a single 
catalase designated Per R which is the regulator and Kat A is iron repressed (175). 
Many species of bacteria utilize their osmo-regulatory mechanisms to cope with 
osmotic stress, but in Campylobacter such system has not been identified yet (120). 
Campylobacter is able to produce cold shock proteins. At temperature as low 
as 4ºC, Campylobacter can still respire, generate ATP, but is unable to replicate. 
However, C. jejuni exhibits chemotaxis even at this low temperature, indicating 
that it may migrate to places which has more favorable conditions and avoid certain 
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environmental stress conditions (176). Overall, these strategies may explain the 
ubiquitous distribution of C. jejuni and its prominent role as an enteric bacterial 
pathogen.  
 
      Epidemiology 
C. jejuni normally lives in gastrointestinal tracts of copious food producing 
animals as a commensal organism. The most prone hosts for Campylobacter are the 
avian species due to their higher body temperature (36, 177). Therefore, C. jejuni 
has a widespread presence in turkeys, chickens, and wild birds such as seagulls and 
geese (178) (179). Carriage of Campylobacter by wild birds results in 
contamination of waterways, and as Campylobacter can survive in water for weeks, 
open waters may serve as a source of infection for poultry and domestic animals 
(54). The majority of Campylobacter infections in humans are associated with 
unprotected handling of raw chicken or consumption of undercooked chicken (180-
182). Campylobacter also commonly exists in many types of food animals other 
than chickens, such as turkeys, cattle, pigs, dairy cows, lamb or duck (183). 
Another significant reservoir for a number of Campylobacter spp. is the digestive 
tract of healthy cattle, in which prevalence ranges at 0-80% (184), while the 
prevalence in sheep is about 20-50% (185). Moreover, high carriage rate of 
Campylobacter in pigs has also been reported (186), but the role of pork in human 
infections does not appear to be a major concern. Besides contaminated poultry 
meat, contact with farm animals and pets, and consumption of raw cow milk and 
untreated water are significant risk factors for human Campylobacteriosis.  
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A recent study (2) by Sahin et. al. concluded that a highly pathogenic C. jejuni 
clone (clone SA) has become the predominant cause of ovine abortions associated 
with  Campylobacter in the United States, indicating that this C. jejuni clone is well 
adapted to ruminants. Furthermore, clone SA was found in healthy sheep and 
cattle, and in cows and goats with abortion, suggesting that the clone SA acts as 
both commensal and a pathogen in ruminants.  
 
Treatment 
C. jejuni infections are often self-limiting and there is usually no rationale for 
antimicrobial treatment, but under certain circumstances, medication can alleviate 
severe symptoms. Antibiotic therapy is often prescribed to patients who are 
immunocompromised or exhibit severe clinical symptoms including bloody 
diarrhea, high fever, pregnancy, and prolonged infection (187). C. jejuni is known 
to be intrinsically resistant to several antibiotics, such as vancomycin, rifampin, 
trimethoprim, amoxicillin, ampicillin, metronidazole, and cephalosporin (1). 
Fluoroquinolones, macrolides, tetracyclines are commonly reserved for the 
treatment of C. jejuni infections. Fluoroquinolones are often used for the empirical 
treatment of enteric infections, because they can alleviate the infection by multiple 
pathogens like Salmonella and Campylobacter (188). Nevertheless, high levels of 
resistance to fluoroquinolones, erythromycin and tetracycline in C. coli and C. 
jejuni strains may weaken the efficiency of the antibiotic treatment (189-192). 
 
 
 
22 
Antimicrobial susceptibility of C. jejuni isolated from food animal production is 
commonly monitored. A recent study by Sahin et. al. suggests oxytetracycline is 
ineffective for Campylobacter-induced abortion in sheep (2). To date, 
erythromycin is considered as the choice for Campylobacter infections because it 
has relatively low resistance in Campylobacter species. Furthermore, erythromycin 
is easy and safe to be administered to immunosuppressed or immune-immature 
patients, such as children and pregnant women (188). Its advantages also include 
low toxicity, low cost, and narrow activity (1). 
 
Prevention and Vaccines 
Since foodstuffs (e.g., poultry meat) is the primary source of Campylobacter 
infection in humans, prevention should take a farm-to-fork approach to reduce the 
infection level among poultry houses, minimize contamination of carcasses in 
processing plants, and ultimately educate consumers for proper handling and 
cooking poultry products. It is necessary to install hygienic barriers between the 
external and internal environments of poultry houses, and implement strict hygienic 
routines such as washing and sanitizing hands, changing boots and coveralls before 
entering into the poultry houses. However, such control measures are often ignored 
on farms (36). Limiting the bacterial load on poultry farms is useful for prevention 
of C. jejuni infections. Additionally, a number of studies have been performed to 
reduce carcass contamination in slaughter houses (193, 194). However, currently 
 
 
 
23 
there are no practical and effective strategies that can be taken in effect to reduce 
Campylobacter colonization in live birds. 
It is widely believed that a vaccine must be able to stimulate intestinal 
immunity to be effective against an enteric bacterial pathogen (15-18). For this 
logistical reason, the oral route of immunization has been identified as the preferred 
approach in the Vaccine Initiative among children (195). It is simpler to administer 
than parenteral immunization. Furthermore, it takes advantage of the huge amounts 
of lymphoid tissue in the oropharynx and intestine. Three different strategies have 
been considered for the development of a reliable vaccine against C. jejuni. The 
first strategy is live attenuated Campylobacter vaccine, which is considered as an 
attractive approach (19). Nevertheless, a study using a viable non-colonizing strain 
of C. jejuni failed to elicit protective immunity in chicks (20). Furthermore, the 
association of the neuropathy and autoimmune disease Guillain–Barre syndrome 
(GBS) with C. jejuni infections impedes the development of whole cell vaccines 
(21). The second one is killed whole cell vaccine, which can offer several 
advantages as potential vaccines for mucosal immunization. Due to their 
microparticle nature, whole dead cells should enhance the interactions between 
their surface and mucosal lymphoid tissues (22). A recent study has demonstrated 
that a limited protection was conferred by C. jejuni killed cells after oral 
vaccination in ferrets (23). Using specific proteins/antigens of Campylobacter as 
subunit protein vaccines is another promising strategy for vaccination. Two 
Campylobacter antigens, PEB1 and flagellin (24, 25), have been evaluated as 
vaccine candidates. However, Campylobacter flagellins have different levels of 
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glycosylation and high antigenic diversity, which makes the development of a 
flagellin-based vaccine problematic (26, 27). A recent study also demonstrates that 
significant levels of anti-PEB serum IgG did not protect against C. jejuni after oral 
challenge in mice (28). 
The above cited vaccine studies and epidemiologic information suggest that 
immune protection against disease caused by C. jejuni is possible. But high amount 
of antigenic variation among different Campylobacter strains causing sheep 
abortion may result in vaccine failure, and result in inadequate amount of cross-
protection produced by the vaccine strain(s) against the field isolates. These 
observations indicate the need for developing a more effective subunit-based 
vaccine incorporating the immunogens of predominant Campylobacter strains 
associated with sheep abortion in the U.S.  
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Abstract 
Campylobacter jejuni clone SA has recently emerged as the prevalent cause of 
Campylobacter-associated sheep abortion in the United States. To develop 
effective vaccines against C. jejuni clone SA in sheep, it is necessary to identify the 
antigens that elicit protective immune responses. Recently, by using 
immunoproteomic approaches we successfully identified a number of clone SA 
proteins that were consistently immunoreactive with multiple convalescent sheep 
and guinea pig sera. In this study, as a first step towards developing an efficacious 
subunit vaccine against sheep abortion, we began to further characterize these 
proteins. Accordingly, 7 clone SA proteins were selected, which included HtrA, 
CgpA, CJSA_0852, Peb4, FabG, MetK and FlgL. Recombinant proteins for each 
of these antigens were produced in an E. coli expression system, and their 
reactivity with a panel of convalescent sera obtained from C. jejuni-infected ewes 
and guinea pigs were tested using immunoblotting. The results showed that CgpA, 
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MetK, FabG had the strongest antigenicity, while HtrA, FlgL and Peb4 were less 
antigenic, and CJSA_0852 had only little reactivity with the sera tested. CgpA, 
HtrA and FlgL were chosen to further evaluate the induction of protective 
immunity against bacterial challenge in the mouse model of systemic infection and 
bacteremia. Immunization of mice with recombinant CgpA, HtrA and FlgL 
induced high level of specific antibodies, but only CgpA-immunized mice showed 
a significant decrease in the level of bacteremia compared with the control mice. 
Analysis of different cellular fractions demonstrated that CgpA is a periplasmic 
protein. These results indicate that CgpA may be a potential subunit vaccine 
candidate against sheep abortion caused by C. jejuni.  
 
Introduction 
Campylobacter spp. is one of the most predominant causes of ovine abortion 
in the United States and worldwide, contributing to an overall abortion rate of 5 to 
50% (average, 23.2%) in affected flocks (1). A national study from the 
USDA/APHIS/Veterinary Services in cooperation with the American Sheep 
Industry Combination to investigate the etiology of sheep abortion indicated that 
Campylobacter species ranked first among infectious causes of abortion in the 
United States, with 8.8% of the sheep producers reporting the cause as 
Campylobacter spp. (2). Campylobacter species can also be carried in the gall 
bladder and intestines of healthy sheep without causing clinical diseases (3-5). In 
addition, Campylobacter is a main cause of bacterial foodborne gastroenteritis in 
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humans worldwide. A latest estimate by the CDC points out that Campylobacter is 
not only among the most popular causes of domestically acquired food-borne 
illnesses in humans (over 800,000 cases per year), but also among the main causes 
of hospitalization (over 8,000 annually) in the United States (6). 
Ovine abortions caused by Campylobacter were ﬁrst reported in Britain 
(McFadyean and Stockman 1913) and have since been reported in most sheep-
rearing countries (7). Historically, Campylobacter fetus subsp. fetus has been 
regarded as the main Campylobacter species associated with ovine abortion. 
However, the proportion of C. jejuni isolates from ovine abortion cases has 
increased steadily during the last two decades and C. jejuni has now replaced C. 
fetus as the predominant Campylobacter species causing sheep abortion in the 
United States (8-11). The most recent examination of the species distribution, 
genotypes and antimicrobial susceptibilities of abortion-associated Campylobacter 
isolates obtained from multiple lambing seasons on different farms in Iowa, Idaho, 
South Dakota and California revealed that 89% of the isolates were identified as C. 
jejuni and the remaining 11% were classified as C. fetus (11). More strikingly, the 
majority (93%) of the C. jejuni isolates associated with sheep abortion belonged to 
a single genetic clone (named sheep abortion, SA clone). Furthermore, zoonotic 
transmission of this emergent clone to humans has been demonstrated by molecular 
and epidemiological evidence, posing an important threat to public health (12). 
These findings indicate that clone SA has evolved to possess novel virulence traits 
and agricultural practices in sheep production in the U.S. may have favored the 
dominance of this hypervirulent clone. 
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A previous immunoproteomics study in our laboratory was conducted to 
characterize the immunogenic antigens from the whole membrane fraction of C. 
jejuni clone SA associated with sheep abortion (13). Twenty-six antigens were 
identified to be strongly recognized by convalescent sheep sera, including 8 
cytoplasmic proteins, 2 cytoplasmic membrane proteins, 11 putative periplasmic 
proteins, 3 outer membrane proteins and 2 extracellular proteins (13).  Since the 
majority of bacterial virulence factors are commonly located on the bacterial cell 
surface or are secreted (14), immune response to membrane-related virulence 
factors is potentially protective against infection. Among all 8 cytoplasmic proteins 
and 2 cytoplasmic membrane proteins, only two cytoplasmic proteins (MetK and 
FabG) that lack a typical signal peptide but predicted to be secreted by SecretomeP 
V2.0 (13) may be considered as potential vaccine candidates against C. jejuni. For 
the 3 outer membrane proteins, the major outer membrane protein MOMP is 
involved in solute transport across the bacterial cell wall and adhesion to the 
intestinal mucosa (15, 16). Recombinant MOMP was shown to provide more than 
42% protective efficacy against intestinal colonization in the mouse model (17). 
VirB10, located in the outer membrane, is not widely distributed among the C. 
jejuni isolated from sheep abortion and thus not suitable as a vaccine candidate for 
C. jejuni-induced sheep abortion. Outer membrane peptide PEB4 is an antigenic 
virulence factor implicated in host cell adhesion, invasion and colonization in 
Campylobacter (18), and its immunogenicity has also been reported in human sera 
(19). The 2 extracellular membrane proteins FlgE and FlgL are both flagellar hook-
associated proteins. The high sequence homology of proteins or antigens among C. 
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jejuni strains may promote the development of broadly protective vaccines against 
C. jejuni infections in sheep. However, FlgE has relatively low identity with its 
homologs in other strains and a previous study indicated that monoclonal 
antibodies raised against FlgE bound exclusively to this antigen (20). For the 11 
periplasmic proteins, most of them have been previously shown to be immunogenic 
and somewhat protective against intestinal colonization in various animal models. 
For example, LivK could protect against intestinal colonization in a mouse model 
(21), whereas ZnuA, CJSA_0392 and CJSA_0679 were not protective in the mouse 
immunization studies (21). CjaA was highly immunogenic and shown to be 
protective in the colonization of chickens when given as an oral Salmonella-
vectored vaccine (22) although the same effect was not repeatable in the follow-up 
studies.  
Vaccines for prevention ovine abortion caused by Campylobacter have been 
used around the world and have been reported to be somewhat effective (23-25). 
Nevertheless, previous experimental studies (24, 26) have indicated that protection 
against either homologous or heterologous Campylobacter challenge in ovine is not 
always obvious following vaccination with commercial vaccines. Moreover, 
Campylobacter associated abortion cases have been also documented in sheep 
flocks given commercial monovalent and bivalent vaccines (27, 28). Therefore, 
improved vaccines are needed to fully protect sheep against abortion caused by 
diverse Campylobacter strains and serotypes (29). Currently, there are two 
commercial Campylobacter vaccines available for controlling sheep abortion in the 
U.S. Both vaccines are killed whole-cell bacterins and contain both C. fetus subsp. 
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fetus and C. jejuni strains. Despite their common use on farms, Campylobacter still 
remains a major cause of ovine abortion [12]. Antigenic variation among different 
Campylobacter strains may result in vaccine failure due to inadequate amount of 
cross-protection produced by the vaccine strain(s) against the field isolates. Thus, 
in addition to whole-cell based bacterin preparations, newer vaccine formulation 
(such as subunit vaccines) incorporating conserved proteins/antigens of C. jejuni 
are needed to elicit a robust immune response against multiple Campylobacter 
genotypes/serotypes associated with sheep abortion. This notion is further 
supported by our group’s recent observation where whole-cell based vaccines 
including the commercial ones and in-house made bacterin provided only limited 
protection against systemic infection/abortion in a pilot study with guinea pigs 
(29). Although a vaccine incorporating three serotypes of C. fetus subsp. fetus plus 
a single strain of C. jejuni has been overall successful in New Zealand 
(CampyVax4), the vaccine may not work in the U.S. because C. jejuni clone SA 
has emerged as the predominant cause of sheep abortion in the U.S. (9). 
Considering the significance of C. jejuni clone SA in causing sheep abortion 
and foodborne illnesses, protective vaccines are needed to control its transmission 
and spread. Recently, in an attempt to identify antigens of clone SA that may be 
useful for vaccine development, we identified a number of recombinant proteins of 
C. jejuni strain IA3902 (a clone SA isolate) that were consistently immunoreactive 
with multiple convalescent sheep and guinea pig sera. In this study, we selected 7 
of these proteins to evaluate their potential as subunit vaccine candidates. The 
selection is based on the predicted functions, cellular localization, consistent sero-
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reactivity, and sequence conservation among C. jejuni. This list included 3 
periplasmic proteins (HtrA, CgpA, CJSA_0852), one outer membrane protein 
(Peb4), two cytoplasmic proteins (FabG and MetK), and one extracellular 
membrane protein (FlgL). Our results suggest that CgpA may be a promising 
subunit vaccine candidate against sheep abortion caused by C. jejuni. 
 
Materials and methods 
Bacterial strains and growth conditions 
C. jejuni strain IA3902 is a clinical isolate of clone SA from an ovine abortion 
case described previously (9), and is the wild-type strain used in this study (Table 
1). It was grown on Mueller-Hinton (MH) agar under microaerobic (5% oxygen, 
10% carbon dioxide and 85% nitrogen) conditions at 42°C for up to 48 h. As 
needed for specific experiments, the culture medium was supplemented with 
Campylobacter selective (polymyxin B, rifampicin, trimethoprim, and 
cycloheximide) and growth (sodium pyruvate, sodium metabisulfite, and ferrous 
sulfate) supplements (Oxoid, Cambridge, England). 
 
Sheep sera and guinea pig sera 
The sheep sera used in this study were collected in 2008 and 2011 from two 
farms where C. jejuni SA clone was epidemic. Serum samples WI, WI96, and 
G190 were all from aborted ewes of the same flock and were collected in 2008. 
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Serum samples 9010, 9417, 9069, 9070, 9078, 9092 and 9097 were all from 
aborted ewes in the same flock and were collected in 2011, but serum 9200 was 
from a non-pregnant ewe in this flock. Each of the serum samples was from a 
different ewe that was infected with a clone SA isolate. The lamb serum sample 
came from a colostrum-deprived neonatal lamb of healthy sheep flock in 2008, 
which had no reported cases of Campylobacter-associated abortion. Whether this 
flock was colonized (in the intestine) by C. jejuni was unknown. Sera A9, A6, B7, 
D1, D11, D2, C6, G4, D5, D10 were all from aborted guinea pigs due to C. jejuni 
clone SA. 
 
Expression and purification of recombinant proteins  
The entire coding sequence without the signal peptide for each protein was 
amplified from C. jejuni IA3902 genomic DNA by PCR. CgpA, HtrA, Peb4, FlgL, 
MetK, FabG and CJSA_0852 coding sequences (not including the N-terminal 
lipoprotein signal peptide sequence) were amplified by PCR using primers specific 
for each gene (Table 2). The amplified products containing specific restriction 
enzyme sites at the 5’-ends and 3’-ends were purified and digested with appropriate 
restriction enzymes and separately ligated into pQE-30 vectors (Qiagen, Valencia, 
CA, USA), resulting in the addition of a 6 × His N-terminal leader sequence to 
each coding sequence. The fidelity of the recombinant plasmid was confirmed by 
sequencing. Plasmids encoding the respective fusion genes were transformed into 
Escherichia coli JM109. Protein induction was then carried out by adding 1 mM 
isopropyl-D-thiogalactoside (IPTG) in shaking bacterial cultures for 3 hours at 
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37°C. Induced cells were harvested and washed with cold PBS and centrifuged at 
8,000 × g for 15 min. The cell pellet was resuspended in Ni-NTA lysis buffer (300 
mM NaCl, 50 mM sodium phosphate buffer, pH 8.0) at 50 g/ mL wet weight. 
Bacteria were lysed by sonication and the lysate was centrifuged at 12,000 × g for 
30 min. Supernatants were then loaded onto a Ni-NTA Superflow Columns 
(Qiagen, Valencia, CA, USA) and the His-tagged proteins were eluted using 
elution buffer containing various imidazole concentrations.  
 
Insertional mutation of cgpA  
 An isogenic cgpA mutant was constructed by insertional mutagenesis in C. 
jejuni IA3902. The kanamycin resistance (KanR; ~1200 bp) cassette was amplified 
from pMW10 (30) with Kan-F and Kan-R primers (Table 2). An 800-bp fragment 
(CgpA1) comprising the first 19 bp of cgpA gene and its upstream flanking region 
was amplified from gDNA of IA3902 via PCR using primers CgpA1F and 
CgpA1R where the reverse primer (44-bp long) was also added with 25 bp that was 
complementary to the 5’-end of the KanR cassette. Another 800-bp fragment 
(CgpA2) containing the last 19 bp of cgpA gene and its downstream flanking 
region was amplified via PCR using the primer set CgpA2F and CgpA2R where 
the forward primer (43-bp long) was added with additional 24 bp complementary 
to the 3’-end of the KanR cassette. CgpA1 fragment and KanR gene were first 
fused together and amplified via PCR using primers CgpA1F and Kan-R (Table 2) 
to obtain CgpA1-KanR. Then, CgpA1-KanR and CgpA2 fragment were merged 
and amplified in a PCR with CgpA1F and CgpA2R to generate CgpA-Kan. The 
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CgpA-Kan construct (~2.8 kb) was introduced into C. jejuni IA3902 by natural 
transformation. Transformants were selected on MH agar containing kanamycin 
(50 µg/ml). Disruption of cgpA in IA3902 by deletion of the most of the ORF and 
insertion of the KanR gene with the correct orientation was confirmed by PCR; the 
cgpA mutant strain was named ΔCgpA. 
 
Preparation of cell fractions 
 The cell fractions of cytoplasm, periplasm, inner membrane, and outer 
membrane were obtained using the methods described previously (31), with slight 
modifications. In total, 500 ml of an overnight culture of C. jejuni strain IA3902 
were harvested by centrifugation at 5000 x g for 30 min, and the cell pellet was 
resuspended in 20 ml of the ST buffer (20% w/v sucrose, 30 mM Tris-HCl, pH 8.0) 
at room temperature. EDTA was added to the cell suspension to a final 
concentration of 1 mM and the suspension was incubated for 10 min at room 
temperature with shaking. The cells were then centrifuged at 8000 x g for 10 min at 
room temperature to collect the cell pellet. The supernatant was discarded. The 
pellet was resuspended and stirred in ice-cold 10 mM Tris-HCl (pH 7.5) at 4 ºC for 
10 min followed by centrifugation at 15,000 x g at 4 ºC for 15 min and it was kept 
as the periplasmic fraction. The pellet was again resuspended in 5 ml of ice-cold 10 
mM Tris- HCl (pH 7.5), followed by sonication (Virsonic, an SP Industries 
Company, Warminster, PA) by three bursts of 30 s at 6 mm amplitude and 
centrifugation at 13,000 x g at 4 ºC for 15 min. The pellet was discarded and the 
supernatant was ultracentrifuged at 100,000 x g at 4  for 1 hour. The supernatant 
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was then transferred to a new tube and again centrifuged at 100,000 x g at 4  for 1 
hour, corresponding to the cytoplasmic fraction. The pellet collected was the total 
membrane fraction. The isolation of inner and outer membrane was performed 
using the method of Carlone et al. (32). The pellet of membrane fraction was 
washed three times with ice- cold 10 mM Tris-HCl (pH 7.5) and resuspended in 0.2 
ml of 10 mM HEPES buffer (pH 7.4). An equal volume of sarkosol buffer (2% 
sodium N-lauroylsarkosine; SIGMA) was added and incubated at room 
temperature for 60 min, during which the solution was mixed occasionally. The 
inner membrane proteins were solubilized at this step. The mixture was centrifuged 
at 15,600 x g for 30 min at 4 . The supernatant was kept as the soluble inner 
membrane fraction. The pellet was washed with 0.5 ml of 10 mM HEPES buffer 
followed by resuspension in 200 ml of 10 mM HEPES buffer. This fraction was the 
outer membrane fraction. The fractions were analyzed by SDS-PAGE and 
immunoblotting. 
 
SDS-PAGE and Western blotting 
Recombinant proteins were separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) with a 4% stacking gel and 10% 
separating gel (18 cm × 16 cm in size; using low florescent glass plates). Protein 
samples were boiled in sample buffer at 100°C for 3 min prior to electrophoresis. 
The SDS-gels were run at 15 °C with parameters as 80V for 30 min, then 200V for 
45 min and stopped until the dye front running out of the gels. For Western 
blotting, the proteins were transferred to LF-PVDF membrane (Millipore, Billerica, 
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MA), and then blocked with the blocking buffer (5% skim milk with 0.1% Tween-
20 in PBS) for 1 h at room temperature. The membrane was incubated with 
primary antibodies (sheep serum and guinea pig serum; 1:100 dilution in the 
blocking buffer) at 4 °C overnight. After three washings with washing buffer (0.1% 
Tween-20 in PBS), the blot was incubated with rabbit anti-sheep or goat anti-
guinea pig conjugated with horseradish peroxidase (Kirkegaard & Perry 
Laboratories, KPL, Gaithersburg, Maryland) (diluted in 1:1000 in the blocking 
buffer) for 1 hour at room temperature. After three washings with the washing 
buffer, the membrane was developed with the 4CN Horseradish Peroxidase 
Substrate system (KPL). The images were captured by a CCD imager 
(AlphaImager® 2200, ProteinSimple, Santa Clara, CA).   
 
ELISA 
An enzyme-linked immunosorbent assay (ELISA) was used to determine the 
level of C. jejuni-specific IgG antibodies in mice. For the bacterin group (positive 
control) and the alum group (sham control), microtiter plates (Nunc-Immune Plate; 
Nunc, Roskild, Denmark) were first coated with 100 µl of whole membrane 
proteins (ca. 60 ng/well) of C. jejuni IA 3902 in coating buffer (sodium carbonate 
[pH 9.6]) overnight at 25°C. For recombinant protein vaccine (CgpA, HtrA and 
FlgL) groups, the microtiter plates were first coated with 100 µl recombinant 
CgpA, HtrA or FlgL recombinant protein, respectively, ( CgpA ca. 960 ng/well; 
HtrA ca. 120 ng/well; FlgL ca.960 ng/well ). Then, plates were incubated with a 
blocking buffer (PBS containing 2% milk, 2% bovine serum albumin, and 0.1% 
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Tween 20) at 37°C for 1 h. Serum samples were diluted in the blocking buffer to 
1:100, and then 100 µl of each dilution was added to individual wells. Duplicate 
wells were used for each sample. After incubation at 25°C for 2 h, the plates were 
washed three times with wash buffer (PBS containing 0.1% Tween 20). Goat anti-
mouse IgG conjugated to peroxidase (Kirkegaard & Perry) was diluted to 1:1,000 
in blocking buffer and added to the wells (100 µl/well). After 2 h of incubation at 
25°C, the plates were washed three times with the wash buffer, and then 2,2’-
azinobis(3-ethylbenzthiazolinesulfonic acid) (ABTS)-peroxidase substrate 
(Kirkegaard & Perry) was added. Optical density (OD) values of individual wells 
were measured using an ELISA reader at 405 nm. Serum samples from 
Campylobacter-colonized sheep (9200 sheep serum) were used as positive control 
in each plate.  
 
Vaccines 
Appropriate amount of purified recombinant proteins of CgpA, HtrA and FlgL 
were dissolved in sterile PBS and mixed with Alhydrogel 2% (alum) (InvivoGen, 
San Diego, California) in 2:1 ratio to give a final concentration of 20µg/100 µl. The 
formulations were rotated at room temperature for 30 min prior to use. A bacterin 
of C. jejuni IA3902, which was demonstrated to provide protection against 
homologous challenge in a previous study (33) was included as positive control. 
For preparation of the bacterin, a frozen stock of C. jejuni IA3902 was grown 
microaerobically on Mueller-Hinton agar for 48 hours at 42°C, and then sub-
passaged on Mueller-Hinton agar for an additional 24 hours at 42°C under the same 
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atmospheric conditions. Colonies of C. jejuni were harvested in PBS solution 
directly from plates by washing and then pelleted by centrifugation (15 minutes at 
7,000 X g). The pellet was washed and resuspended in 10 mL of PBS solution 
containing 0.3% formalin. This suspension was centrifuged again (30 minutes at 
7,000 X g), the supernatant was discarded, and the washing process repeated 2 
times. The final pellet was weighed and resuspended in sterile PBS solution to 
achieve a final concentration of 5 mg of C. jejuni cells/mL. This final concentration 
was selected on the basis of a previous report comparing antigen dose and various 
adjuvant types in which this concentration provided 93% protection against 
homologous challenge (33). A few drops of the diluted cells were streaked on 
Mueller- Hinton agar or added to enrichment broth, both of which were placed in a 
microaerophilic environment to evaluate efficacy of formalin killing. The bacterin 
and Alhydrogel 2% were mixed in a ratio of 2:1 and the volume was adjusted to 
100 µl /mouse. Alhydrogel 2% mixed with sterile PBS in 1:2 ratio was included as 
negative control (sham vaccine). 
 
Mouse immunization and challenge experiments 
A key step in Campylobacter-induced abortion is the development of 
bacteremia. Previously we have developed a mouse model to evaluate bacteremia 
induced by C. jejuni clone SA (34). This model was used in this study to assess the 
immunogenicity of the selected recombinant proteins. Wild-type HA-ICR (CD-1) 
female mice at 8-10 weeks of age were purchased from Charles River Laboratories 
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(Wilmington, MA) and maintained by Laboratory Animal Resources at the College 
of Veterinary Medicine at Iowa State University. All animal experiments were 
approved by the Iowa State University Institutional Animal Care Committee. The 
mice were housed in polycarbonate microisolator cages with bedding (4-5 
mice/cage) and provided with water and a commercial feed ad libitum. The animals 
were acclimated for a minimum of three days before being used for experiments. 
Mice were injected subcutaneously twice at 2 weeks interval with 100 µl of each of 
the recombinant protein vaccine and control formulations described above (16 
mice/group). Blood samples (~0.1-0.2 ml) were taken from saphenous vein using a 
25G needle 2 weeks after the second immunization. Serum was obtained from each 
blood sample and used in ELISA to determine the antibody levels specific for each 
vaccine.  
Seventeen days after the second immunization, the mice were challenged with 
C. jejuni IA3902. This strain used for inoculation was recovered from a freezer 
stock (-80°C, 20% glycerol), plated on selective medium and incubated for 48 h as 
described above. Bacterial cultures obtained from these plates were sub-passaged 
under the same conditions for 18 h. Fresh cultures were harvested and suspended in 
MH broth, diluted to the desired cell density based on optical density (OD600 =1), 
and subsequently confirmed by viable counts. Ten mice from each immunized 
group were challenged and each mouse received 100 µl bacterial culture 
(approximately 1 x 108CFU/mouse) via gastric gavage using a curved, ball-tipped, 
18-gauge, 2-inch needle, under light sedation with 2% isoflurane as previously 
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described (35). Additionally, 6 mice for each vaccine group were not inoculated, 
and were used solely for serum collection from the heart blood.  
 
Quantitation of systemic infection 
Mice were euthanized at 8 h post-inoculation via intraperitoneal (IP) injection 
of a ketamine/xylazine mixture followed by exsanguination. Fecal swabs were 
taken from the non-inoculated mice at necropsy to confirm all mice were 
Campylobacter-free and no cross contamination occurred. Samples harvested for 
Campylobacter culture included cardiac blood and liver. Cardiac blood was 
collected by use of a sterile tuberculin syringe with a 22-gauge needle and placed 
in blood collection tubes (0.5 mL Greiner Vacuette MiniCollect K3 EDTA, Fisher 
Scientific). Within a couple of hours of sample collection, 250 µL of undiluted 
blood and appropriate serial dilutions thereof were plated on selective medium and 
incubated for 48 h under microaerobic conditions. Liver tissues were placed in a 
separate sterile plastic bag (Whirl-Pak bags, Nasco, Fort Atkinson, WI), weighed, 
homogenized in MH broth, serially diluted, plated on selective medium and 
incubated for 48 h. C. jejuni recovery was expressed as log10 CFU/ml blood or g of 
liver. 
 
      Statistical analysis 
A Fisher exact test for binomial variables was used when comparing 
Campylobacter culture results in experimental and control vaccine groups of mice. 
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A 1-way ANOVA was used to detect differences in ELISA results, and a Tukey’s 
adjustment for multiple comparisons was made. A p value of ≤ 0.05 was used in 
ELISA result to determine significant differences in antibody levels whereas p ≤ of 
0.1was used to evaluate significant differences in bacteremia in challenge 
experiments. 
 
Results 
Production of recombinant antigens 
Seven proteins including CgpA, CJSA_0852, FabG, MetK, HtrA, FlgL, Peb4 
of C. jejuni IA3902 were cloned and expressed in E. coli as recombinant proteins. 
These antigens were chosen for further evaluation since they all had strong and 
consistent reactivity with convalescent sera as determined in a previous 
immunoproteomics study (13). The recombinant proteins were successfully 
prepared and purified from E. coli (Figure 1). All of 7 recombinant proteins were 
soluble in water and showed the expected sizes (Table 3) on SDS-PAGE. However, 
HtrA had two bands, in which the top one matched the excepted size, which is 
51kDa. Previous study demonstrated that mature HtrA was partially degraded both 
in vivo and in vitro due to self-cleavage following Cys69 and Gln82 of the mature 
protein (36, 37). The cleaved protein was also called short-HtrA (37). Then the 7 
recombinant proteins were purified and blotted by a convalescent sheep serum. The 
results showed that all the recombinant proteins were reactive to the serum (Figure 
1). Both bands of HtrA can be recognized by the convalescent sheep serum.  
 
 
 
60 
The purified recombinant proteins were further blotted with 11 convalescent 
sheep sera from aborted ewes due to natural infection with clone SA and 10 
convalescent sera from guinea pigs aborted due to experimental infection with C. 
jejuni IA3902. The results showed that, except for CJSA_0852, all other six 
recombinant antigens were reactive with all of the tested sera (Figure 2). However, 
the strength of reactivity varied markedly with different antigen-serum 
combinations (Figure 2). In general, the convalescent sheep sera reacted more 
strongly with all recombinant proteins than the sera from the aborted guinea pigs 
(Figure 2). This was not surprising since sheep sera were collected from naturally 
infected and aborted ewes with longer duration of infection (~months) whereas the 
guinea pig sera were obtained from experimentally infected and aborted animals 
with much shorter duration of infection (~ a few days to 3 weeks). Immunogenicity 
of each protein is considered as one of the important factors for selecting promising 
vaccine candidates. The stronger the reactivity of the antigen with convalescent 
sera from sheep and guinea pig is, the more likely the antigen may elicit an 
effective immune response in vaccinated animals. Consequently, we selected 3 of 
these proteins (CgpA, HtrA, and FlgL) as potential subunit vaccine candidates on 
the basis of predicted functions (novel or previously suggested as a good vaccine 
candidate or a virulence factor), cellular localization (surface associated or 
secreted), consistent sera-reactivity with convalescent sera, and sequence 
conservation among C. jejuni (Table 3). These three antigens were further 
characterized in detail and evaluated for the induction of protective immunity 
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against oral bacterial challenge in a mouse model of systemic infection and 
bacteremia. 
 
Immunogenicity of the recombinant subunit vaccines in mice  
No apparent side effects were noted in mice following subcutaneous injections 
of any of the vaccine formulations including the recombinant subunit (rCgpA, 
rHtrA and rFlgL) and the control (bacterin and sham) vaccines, indicating their 
safety. Levels of specific IgG antibodies in the systemic circulation for each 
vaccine was determined 2 weeks after the second immunization using ELISA 
plates coated with the corresponding antigen. The results showed the production of 
high-level specific antibodies in animals immunized with each of the subunit 
vaccines or the bacterin, compared with the sham-vaccine (alum only), which only 
induced very weak antibody response (Figure 3A). The sera from animals 
immunized with each vaccine also strongly reacted with whole membrane proteins 
of C. jejuni IA3902 (Figure 3B), which demonstrates that these subunit vaccines 
induced specific antibody that recognize not only recombinant antigens, but also 
native proteins expressed in Campylobacter. Specific antibody can react with their 
specific recombinant protein stronger than whole membrane protein, which can be 
reflected by the lower OD value of recombinant protein in Figure 3B. This finding 
showed that CgpA, HtrA and FlgL are all highly immunogenic in mice when given 
S.C. in combination with alum, suggesting their feasibility as subunit vaccine 
candidates against Campylobacter-induced abortion. 
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Efficacy of recombinant subunit vaccines in mice  
To assess the potential of the recombinant subunit vaccines in protecting mice 
from bacteremia, the mice (n=10 per group) were orally challenged with C. jejuni 
IA3902 17 days after the second immunization with the corresponding vaccine. At 8 
h after the inoculation, cardiac blood and liver tissues were collected and cultured for 
C. jejuni. The number of mice positive with bacteremia and/or liver infection was 
used to measure the protective ability of each vaccine (Figure 4). Compared with the 
control (sham vaccine) group in which 50% of blood samples yielded 
Campylobacter growth (with the mean log10 CFU/ml being 0.97), only 10% of mice 
showed evidence of bacteremia in rCgpA vaccine group (mean log10 CFU/ml: 0.24) 
(p ≤ 0.1). In the rHtrA vaccine group, 40% of mice were bacteremic with mean of 
bacteremia rate at 0.85 log10 CFU/ml (p>0.1). In the group of mice immunized with 
the bacterin, none of the animals developed detectable levels of bacteremia (p ≤ 
0.1)(Figure 4). Values of p ≤ 0.1 were considered significant. Since the liver plays a 
potential role in clearing C. jejuni from the bloodstream, homogenized liver tissues 
were also cultured. In general, quantitative cultures of the livers of the orally 
infected mice yielded much less Campylobacter compared with those in the 
bloodstreams for all groups irrespective of the vaccine they received (Figure 4). 
Only 10% of mice showed evidence of liver infection in rCgpA vaccine group while 
both the rHtrA vaccine and sham groups had 20% of mice being Campylobacter 
culture positive in the liver. None of the mice were positive for Campylobacter 
culture in the liver of bacterin group (Figure 4). The differences in Campylobacter 
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positivity in the liver of different vaccine vs. control groups were not statistically 
significant. In the second experiment, the protective capacity of rFlgL subunit 
vaccine was assessed. Although 80% of the vaccinated mice did not have 
Campylobacter recovered in the blood/liver, the validity of this data was not assured 
due to the extremely low-level bacteremia (10%) in the sham control group (data not 
shown). Together, the results from the immunization/challenge experiments indicate 
the high immunogenicity of the all three recombinant proteins, and further suggest 
that subunit vaccine formulations incorporating CgpA could be a potential candidate 
for protection against C. jejuni-induced abortion in sheep.  
 
CgpA is a periplasmic protein 
In order to determine the cellular localization of CgpA, C. jejuni strain IA3902 
was fractionated to isolate proteins from the periplasm, cytosol, inner membrane and 
outer membrane. The fractions were examined by immunoblotting with anti-rCgpA 
antibodies produced in mice (Figure 5). CgpA was detected as multiple bands 
predominantly in the periplasmic fraction (Figure 5A). This result is consistent with 
the fact that CgpA in C. jejuni is modified by differential levels of glycosylation 
with neutral sugar residues (38). Interestingly, the CgpA bands showed larger sizes 
when the whole-cell extract of C. jejuni IA3902 was blotted with anti-rCgpA 
antibody (Figure 5B, lanes 3 and 4). On the other hand, the recombinant CgpA 
produced in E. coli was not glycosylated and was shown as a single band (Figure 5B, 
lane 1), which was smaller in size than the multiple forms of the native protein 
detected in the periplasmic fraction and the whole-cell extract. This finding further 
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indicated that glycosylation affects the migration patterns of glycosylated proteins on 
SDS-PAGE. As control, an isogenic CgpA mutant strain was blotted with the anti- 
rCgpA antibody, which showed no apparent reaction (Figure 5B, lane 2). 
Additionally, we used CmeB, CmeR and MOMP as controls for various fractions 
and they were predominantly detected in the inner membrane, cytoplasmic and outer 
membrane fractions, respectively (Figure 5A), consistent with the previous findings 
that CmeB is an inner membrane protein (39), CmeR is a cytoplasmic protein (40), 
and MOMP is an outer membrane protein (41). These results confirm the predicted 
periplasmic location of CgpA in C. jejuni. 
 
Discussion 
Campylobacter jejuni clone SA is the predominant cause of sheep abortion in 
the United States and incurs a significant economic loss to sheep producers. In 
order to identify the proteins of clone SA that may be useful for vaccine 
development, we recently employed an immunoproteomics approach to identify the 
immunoreactive antigens of C. jejuni IA3902 (a clone SA strain). The result 
suggested 7 such proteins on the basis of their consistent reactivity with multiple 
convalescent sheep and guinea pig sera. This list included 3 periplasmic proteins 
HtrA, CgpA, CJSA_0852, one outer membrane protein, Peb4, two cytoplasmic 
proteins, FabG and MetK, and one extracellular membrane protein FlgL. In this 
study, we selected 3 of these proteins (CgpA, HtrA, and FlgL) based on the 
predicted functions, cellular localization, consistent sero-reactivity, and sequence 
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conservation among C. jejuni, and further evaluated their potential for protection 
against bacteremia in mice. Our results suggest that CgpA may be a promising 
subunit vaccine candidate against sheep abortion caused by C. jejuni. 
As a major foodborne pathogen, Campylobacter is widely distributed in food 
producing animals (42). Despite the recent advancements in understanding its 
ecology and its increasing global importance in animal health as well as public 
health, research on vaccines against Campylobacter is still in its infancy. Several 
strategies have been evaluated for developing vaccines against C. jejuni infections 
or disease. Using genetics to develop live attenuated Campylobacter vaccines (43) 
was proposed to be a promising approach. However, a study using a viable non-
colonizing strain of C. jejuni failed to provoke protective immunity in chicks (44). 
Furthermore, the association of the neuropathy and autoimmune disease Guillain–
Barre syndrome with C. jejuni infections makes the development of whole-cell 
human vaccines problematic (45). Killed whole-cell vaccines, which are naturally 
occurring microparticles, have several advantages as potential vaccines when 
formulated with appropriate adjuvants for mucosal immunization. They can 
enhance the interaction between their mucosal lymphoid tissue and surface (46). A 
recent study demonstrated that oral vaccination with killed C. jejuni cells can only 
provide a limited protection of ferrets (47). Cross protection against major 
serotypes of Campylobacter is probable but it proves to be difficult due to genetic 
and antigenic variations. Using subunit antigens or native proteins of 
Campylobacter purified and isolated from the bacterial surface as vaccines is 
another possible method for vaccination. Two Campylobacter antigens, a protein 
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called PEB1 and flagellin (48, 49) have been advised as Campylobacter vaccine 
candidates. However, Campylobacter flagellins have diverse antigenicity and the 
fact that immunogenic flagellin proteins need to be glycosylated, which may 
impede the development of a flagellin-based vaccine (50, 51). Additionally, a 
recent study demonstrated that significant levels of anti-PEB serum IgG did not 
protect vaccinated mice against C. jejuni after oral challenge (52). 
Almost all bacterial virulence factors are located on the cell surface of bacteria 
or are secreted (14). Antibodies to membrane-related virulence factors could 
neutralize the virulence antigens and cease the pathogenic process. Periplasmic 
proteins possess a short N-terminal motif, which is known to be the reason of their 
transport to the periplasm, but no signal sequences can be identify to lead their 
transport to the bacterial surface. However, it is possible that periplasmic proteins 
could still be exposed to surface after being transported to the periplasm (13). For 
example, cytolethal distending toxin (CDT) can be transported from periplasm to 
bacteria surface by outer membrane vesicles (OMVs) (53). Thus, common 
immunogenic nature of the clone SA periplasmic proteins identified in this study is 
not surprising since these proteins can be exposed on the bacterial cell surface (or 
secreted) and readily recognized by the host immune system. Therefore, depending 
on their biological functions, specific antibodies produced against periplasmic 
antigens could interfere with pathogenesis of bacterial infections, indicating the 
feasibility of development of effective subunit vaccines formulated with such 
proteins. 
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CgpA, a 220 aa-long and N-linked glycosylated periplasmic protein in C. 
jejuni, is commonly recognized by convalescent sera from infected animals (13). 
Previous studies have evidenced that C. jejuni has an N-linked protein 
glycosylation pathway that is indispensable for efficient cell invasion (54). N-
linked glycosylated proteins might be involved in adherence, invasion and 
colonization in C. jejuni (55-61). Linton et al. also presented evidence indicating 
CgpA as a N-linked GalNAc-containing glycoprotein (62). In this study, a subunit 
vaccine incorporating rCgpA and alum adjuvant was shown to be highly 
immunogenic following two S.C. injections in mice, as measured by high levels of 
IgG in systemic circulation. Moreover, the same vaccine was found to confer a 
significant level of protection against bacteremia and liver infection in mice orally 
challenged with the homologous strain. Thus CgpA is a potential vaccine candidate 
for C. jejuni abortion in sheep. Future studies on the protective role of CgpA-based 
subunit vaccines using pregnant animal disease models (e.g., guinea pigs and 
sheep) are warranted.  Interestingly, CgpA showed multiple bands in both whole 
cell extract and periplasmic fraction (Figure 5B). However, the bands in the whole-
cell extract of C. jejuni IA3902 were larger than those in the periplasmic fraction. 
The size discrepancy is probably due to the chemical and physical treatment used 
in the purification of different fractions, which may have caused breakage of 
glycosylated chains and resulted in smaller size bands in the periplasmic fraction.   
The periplasmic protein HtrA has both protease and chaperone activity and is 
required for efficient binding to epithelial cells in C. jejuni (63). Another study 
showed that HtrA could be secreted during infection with an unknown mechanism 
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and HtrA’s protease activity played a key role in rapid crossing of the intestinal 
epithelial barrier (64). Although a previous study demonstrated that HtrA mutants 
of Salmonella and Yersinia strains protected mice from subsequent challenge with 
virulent strains (65), a rHtrA-based subunit vaccine did not show apparent 
protection against bacteremia in mice in our study. FlgL is a flagellar hook-
associated protein and a novel immunogen of C. jejuni identified recently by 
proteomics (13). Bacterial outer membrane proteins, due to the direct interaction 
with the host cells and being potential pathogenicity factors, are good vaccine 
candidates. Although the rFlgL-based subunit vaccine was found to elicit a high-
level antibody response in immunized mice, the protective role of this vaccine 
could not be measured in this study due to unexpected issues with the animal 
model. 
Guinea pigs have been represented as a well-established model to study 
Campylobacter-induced abortion by previous studies (66-68), because the induced 
disease is similar to that seen in sheep and they are susceptible to Campylobacter. 
Although the model is available for researching Campylobacter-induced abortion, 
it is time consuming, cumbersome, and expensive. Therefore, using pregnant 
guinea pigs is not always feasible for large-scale studies involving multiple 
experiments. Previously, we developed a tractable and inexpensive mouse model to 
study bacteremia/systemic infection induced by C. jejuni (34). Since the process of 
bacteremia/systemic infection is a key prerequisite in the pathogenesis of 
Campylobacter induced sheep abortion, we reasoned that our mouse model would 
also be a suitable screening tool for evaluating a large number of subunit proteins 
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for in-vivo immunogenicity and vaccine potential. In this study using the mouse 
model, we significantly narrowed down the number of antigens to be evaluated as 
promising vaccine candidates in more relevant (but highly expensive and complex) 
animal models using pregnant guinea pigs and/or sheep. Unexpectedly, our second 
challenge experiment with rFlgL vaccinated mice failed because of extremely low-
level bacteremia even in the sham control group. Although the mice were from the 
same commercial source and were confirmed Campylobacter-free, they might have 
developed resistance to Campylobacter for unknown reasons. Additional 
experiments are needed to assess the protection of rFlgL.    
 
Conclusion 
In conclusion, our finding showed that CgpA, HtrA and FlgL are all highly 
immunogenic in mice when given S.C. in combination with alum, suggesting their 
feasibility as subunit vaccine candidates against Campylobacter-induced abortion. 
Furthermore, the results suggest that subunit vaccine formulations incorporating 
CgpA could be a potential candidate for protection against C. jejuni-induced 
abortion in sheep. Future studies are needed to evaluate the functions of these 
recombinant proteins in protection against ovine abortion caused by C. jejuni using 
more relevant disease models including pregnant guinea pigs and sheep. 
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Strain or Plasmid     Description a 
 
Reference 
C. jejuni   
    
 
IA3902  Wild type    
 
   (9) 
 
 ΔCgpA 
mutant    IA3902 derivative CgpA:: kanr     This study 
E. coli 
    
 
JM 109       
endA1 recA gyrA96 thi 
hsdR17(rk2,mk+) relA1supE44D(lac 
proAB)[FreaD36proABlacIqZDM15]    Promega 
Plasmid 
    
 
 pQE30   E. coli cloning vector   Qiagen  
 
pMW10  
E. coli-C. jejuni shuttle vector with 
promoter less E. coli lac Z gene, kanr      (69) 
 
a kanr confers kanamycin resistance 
Table 1. Bacterial strains and plasmids used in this study. 
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Primers Sequence (5’ to 3’)a 
    pQE30_F CCCGAAAAGTGCCACCTG 
    pQE30_R GTTCTGAGGTCATTACTGG 
   CgpA_F CGCGGATCCGATGAAATCCTTTCAAGAC(BamHI) 
  CgpA_R CCCAAGCTTTCAAAGCAGATTAATCATATATC(HindIII) 
  MetK_F CGGGGTACCTATCTATTCACTTCAGAAGTCGTAA(KpnI) 
  MetK_R CCCAAGCTTTTAAAGTAGCTTTTTAAACTGTTCT(HindIII) 
 Peb4_F CGCGGATCCGCTACAGTAGCTACTGTTAATGGCA(BamHI) 
 Peb4_R CGGGGTACCTTATTTATATTCCACTTTAGCACTA(KpnI) 
  FabG_F CGCGGATCCAAATTTAGTGGAAAAAATGTTTTAA(BamHI) 
 FabG_R CGGGGTACCTTACATATATAAACCACCATTGATC(KpnI) 
  CJSA_0852_F CGGGGTACCTCAGATCTTGTTAAAATTTATCTTA(KpnI) 
  CJSA_0852_R CCCAAGCTTTTATTGCTCTGCTAAAATTTTCATT(HindIII) 
  HtrA_F CGCGGATCCAATCGTGTGAATCCTGCTGCT(BamHI) 
  HtrA_R CGGGGTACCTTATTTAAGCACAAGCAAAGTCGC(KpnI) 
  FlgL_F CGCGGATCCAGAATTACAAATAAACTTAAC(BamHI) 
  FlgL_R TCCCCCGGGTTACATATAATTTAATAAGCTAAG(SmaI) 
  CgpA_1F CCATAACCTACAGATCCGAA 
   CgpA_1R  CATTCTATAGATATATTGATAAGCGAAACATACGCCTTAGCAAT 
 CgpA_2F TTTAGTGATTGTCTTAGCATTATCCTTATCTTCACTTCCGTCT 
 CgpA_2R GGAATGCCTTTATATCGCTA 
   Kan_F CGCTTATCAATATATCTATAGAATG 
   Kan_R GATAATGCTAAGACAATCACTAAA 
   
a The underlined sequences in the primers indicate the restriction sites for specific restriction 
enzymes, which are shown in parenthesis.  
Table 2. Primer sequences used in this study. 
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 CgpA CJSA_0852 HtrA FabG MetK Peb4 FlgL 
Antigenicity* +++ + ++ +++ +++ ++ ++ 
Predicted 
Function 
 
Unknown  
 
Unknown 
Serine 
protease/ 
chaperone 
 
Reductase 
 
Synthetase 
Major 
antigenic 
peptide 
 
Motility 
Degree of 
conservation¶ 
Well- 
conserved 
Well- 
conserved 
Well- 
conserved 
Well- 
conserved 
Well- 
conserved 
Well- 
conserved 
Well- 
conserved 
Novelty Yes Yes Yes Yes Yes No Yes 
Protein 
MW(KDa) 
 
25.28 
 
37.74 
 
51.01 
 
26.46 
 
43.65 
 
30.52 
 
81.98 
Location Periplasm Periplasm Periplasm Cytoplasm Cytoplasm Periplasm Cell 
surface 
Table 
Table 3. Characteristics of C. jejuni recombinant proteins evaluated for subunit 
vaccine potential in this study. 
*Based on reactivity with sheep and guinea pig sera of infected/aborted animals. 
¶Based on sequence similarity among C. jejuni isolates from sheep abortions 
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   A 
B 
Figure 1. Expression and purification of 7 recombinant antigens from C. jejuni IA3902 with 
convalescent sheep sera. (A) SDS-PAGE image of the purified recombinant proteins. The 
identity of each protein is labeled underneath the panels. (B) Immunoblotting image of 
recombinant antigens with sheep serum 9010. HtrA shows two specific bands due to its auto-
cleavage during maturing.  
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GP 
GP 
GP 
GP 
GP 
Figure 2. Immunoblot analysis of the 7 recombinant proteins of C. jejuni IA3902 with convalescent 
sera. For each recombinant protein, the results are shown for 11 sheep sera (SP) and 10 guinea pig 
sera (GP). For sheep sera, the serum numbers refer to animal IDs 9010, 9069, 9070, 9078, 9092, 
9097, 9417, 9200, WI, WI96, and G190, respectively. For guinea pig sera, the lane numbers 
correspond to animal IDs A9, A6, B7, D1, D11, D2, C6, G4, D5 and D10, respectively. HtrA 
shows two bands, which are indicated by arrows.  
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Figure 3. Immunogenicity of alum-adjuvanted recombinant proteins (CgpA, 
HtrA, and FlgL) and bacterin of C. jejuni IA3902 in mice. Systemic IgG ELISA 
levels specific for each recombinant proteins were measured 2-weeks after the 
2nd immunization with the respective antigen given s.c. at two weeks intervals. 
(A) In CgpA, HtrA, FlgL and Bacterin groups, the sera (black bars) were tested 
with their corresponding antigens coated onto plates in comparison with the sera 
from the sham control group (grey bars). (B) Sera from each group were tested 
with whole membrane protein as the coating antigen on plates. *p < 0.05 
indicates significant differences. 
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Figure 4. Protective effect of recombinant subunit vaccines against C. jejuni IA3902 in 
mice. CD-1 mice vaccinated with the corresponding recombinant protein as described in 
Figure 2 or bacterin were orally challenged with IA3902 (~108 CFU/mouse) and were 
necropsied at 8 hour post-inoculation. Levels of bacteremia (Figure 3A) and liver infection 
(Figure 3B) were determined as described in materials and methods. Each bar represents 
percentage of infected mice in each vaccine group. Statistically significant differences are 
shown at *p < 0.1. **P > 0.1 in liver infection shows no significant differences.  
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Figure 5. Identification of CgpA as a periplasmic protein in C. jejuni IA3902. (A) The 
periplasmic (lane 1), cytosol  (lane 2), inner membrane (lane 3), and outer membrane 
fractions (lane 4) were separated by SDS-PAGE and probed with anti-rCgpA (panel A-
I), anti-rCmeR (panel A-II), anti-rCmeB (panel A-III), and anti-rMOMP (panel A-IV) 
antibodies, respectively. (B) Recombinant CgpA (lane 1), whole cell lysate of CgpA 
mutant (lane 2), whole cell lysate of wild type IA3902 (lane 3), and the periplasmic 
fraction (lane 4) of IA3902 were separated by SDS-PAGE and probed with anti-rCgpA. 
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CHAPTER 3. GENERAL CONCLUSION 
 
Campylobacter jejuni is one of the most predominant causes of ovine abortion 
in the United States and worldwide. Our work recently demonstrated the majority 
(93%) of the C. jejuni isolates associated with sheep abortion belonged to a single 
genetic clone (named sheep abortion, SA clone). Considering the significance of C. 
jejuni clone SA in causing sheep abortion and foodborne illnesses, protective 
vaccines are needed to control its transmission and spread. In an attempt to identify 
antigens of clone SA that may be useful for vaccine development, a previous 
immunoproteomics study in our laboratory was conducted to characterize the 
immunogenic antigens from the whole membrane fraction of C. jejuni clone SA 
associated with sheep abortion. Twenty-six antigens were identified to be strongly 
recognized by convalescent sheep sera. 
In this study, we produced recombinant proteins of C. jejuni strain IA3902 (a 
clone SA isolate) that were consistently immunoreactive with multiple 
convalescent sheep and guinea pig sera. We selected 7 of these proteins to evaluate 
their potential as subunit vaccine candidates. The selection is based on the 
predicted functions, cellular localization, consistent sero-reactivity, and sequence 
conservation among C. jejuni. This list included 3 periplasmic proteins (HtrA, 
CgpA, CJSA_0852), one outer membrane protein (Peb4), two cytoplasmic proteins 
(FabG and MetK), and one extracellular membrane protein (FlgL). Recombinant 
proteins for each of these antigens were produced in an E. coli expression system, 
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and their reactivity with a panel of convalescent sera obtained from C. jejuni-
infected ewes and guinea pigs were tested using immunoblotting. The results 
showed that CgpA, MetK, FabG had the strongest antigenicity, while HtrA, FlgL 
and Peb4 were less antigenic, and CJSA_0852 had only little reactivity with the 
sera tested. CgpA, HtrA and FlgL were chosen to further evaluate the induction of 
protective immunity against bacterial challenge in the mouse model of systemic 
infection and bacteremia. Immunization of mice with recombinant CgpA, HtrA and 
FlgL induced high level of specific antibodies, but only CgpA-immunized mice 
showed a significant decrease in the level of bacteremia compared with the control 
mice. Analysis of different cellular fractions demonstrated that CgpA is a 
periplasmic protein.  
Together, our finding showed that CgpA, HtrA and FlgL are all highly 
immunogenic in mice when given S.C. in combination with alum, suggesting their 
feasibility as subunit vaccine candidates against Campylobacter-induced abortion. 
Furthermore, the results suggest that subunit vaccine formulations incorporating 
CgpA could be a potential candidate for protection against C. jejuni-induced 
abortion in sheep. Future studies are needed to evaluate the functions of these 
recombinant proteins in protection against ovine abortion caused by C. jejuni using 
more relevant disease models including pregnant guinea pigs and sheep. 
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